3000
N. B. Nabulsi et al. / Bioorg. Med. Chem. 13 (2005) 2993–3001
1
for [ C]Gly-Sar and [ C]cyclo(Gly-Sar) in CD-1 mice:
1
11
8. Shen, H.; Smith, D. E.; Keep, R. F.; Brosius, F. C., III.
Mol. Pharm. 2004, 1, 248.
1
[
4
2 frames each; 5 · 2 min + 4 · 5 + 3 · 10; (ii) for
1
1
9
. D o¨ ring, F.; Walter, J.; Will, J.; F o¨ cking, M.; Boll, M.;
Amasheh, S.; Clauss, W.; Daniel, H. J. Clin. Invest. 1998,
101, 2761.
C]Gly-Sar in PepT2 mice: 15 frames each;
· 0.5 min + 3 · 1 + 2 · 2.5 + 2 · 5 + 4 · 10. A model-
4
4
based normalization specific to the microPET scanner
geometry and block design was applied to the sonogram
data. Data were also corrected for random coincidences,
dead time, attenuation, and scatter. Images were recon-
structed using fully 3-D maximum a-posteriori (MAP)
1
0. Berger, U. V.; Hediger, M. A. Anat. Embryol. (Berl) 1999,
99, 439.
1
1. Groneberg, D.; Doring, F.; Nickolaus, M.; Daniel, H.;
1
Fischer, A. Neurosci. Lett. 2001, 304, 181.
12. Nussberger, S.; Hediger, M. Exper. Nephrol. 1995, 3,
211.
13. Palacin, M.; Estevez, R.; Bertran, J.; Zorzano, A. Physiol.
Rev. 1998, 78, 969.
4. Rubio-Aliaga, I.; Frey, I.; Boll, M.; Groneberg, D. A.;
Eichinger, H. M.; Balling, R.; Daniel, H. Mol. Cell Biol.
2003, 23, 3247.
15. Shen, H.; Smith, D. E.; Keep, R. F.; Xiang, J.; Brosius, F.
C., III. J. Biol. Chem. 2003, 278, 4786.
6. Tett, S. E.; Kirkpatrick, M. J.; Gross, A. S.; McLachlan,
A. J. Clin. Pharmacokinet. 2003, 42(14), 1193.
17. Lam, Y. W.; Banerji, S.; Hatfield, C.; Talbert, R. L. Clin.
Pharmacokinet. 1997, 32, 30.
18. Daniel, H.; Herget, M. Am. J. Physiol. 1997, 273, F1.
4
5
3
0 iterations. Regions of interest (ROI) corresponding
to the renal medulla and pelvis were drawn manually on
multiple slices (i.e., 3-D) of specified frame of each dy-
namic sequence and applied to all other frames gene-
rating time-activity curves: (i) CD-1 mice: for
1
1
1
1
1
[
[
C]cyclo(Gly-Sar), frame 0 (2 min post-injection); for
C]Gly-Sar, frame 4 (10 min post-injection); (ii)
À/À
11
PepT2
post-injection); (iii) PepT2
frame 9 (15 min post-injection).
mouse: for [ C]Gly-Sar, frame 2 (1.5 min
1
+
/+
11
mouse: for [ C]Gly-Sar,
4
.3. Ex vivo biodistribution studies
1
2
9. Adibi, S. A. Ciba Found. Symp. 1977, 50, 265.
0. Adibi, S. A.; Krzysik, B. A. Clin. Sci. Mol. Med. 1977, 52,
Groups of mice (four animals) were anesthetized with
diethyl ether and injected via the tail vein with a saline
diluted solution of radiotracer (20–300 lCi in 25 mmol
2
05.
2
2
2
1. Hidalgo, I. J.; Bhatnagar, P. L. C. P.; Miller, J.; Cucullino,
G.; Smith, P. L. Pharm. Res. 1995, 12, 317.
2. Mizuma, T.; Masubuchi, S.; Awazu, S. J. Pharm. Phar-
macol. 1998, 50, 167.
3. Terada, T.; Sawada, K.; Saito, M.; Hashimoto, Y.; Inui,
K.-I. Eur. J. Physiol. 2000, 440, 679.
24. Wagner, J. G. Fundamentals of Clinical Pharmacokinetics;
NH OAc). Animals were allowed to recover, reanesthe-
4
tized and sacrificed at 5, 10, 30 or 40 min post-injection.
The organs were rapidly removed, weighed and then
counted for carbon-11 using an automatic gamma coun-
ter (Packard Auto Gamma 5780). Counts were decay
corrected to the time of injection to determine the per-
cent injected dose per gram tissue (%ID/g) for each
organ.
Drug Intelligence Publications: Hamilton, IL, 1975.
2
5. Daniel, H.; Morse, E. L.; Adibi, S. A. J. Biol. Chem. 1992,
67, 9565.
6. Goolcharran, C.; Borchardt, R. J. Pharm. Sci. 1998, 87,
83.
27. Purdie, J.; Benoiton, N. L. J. Chem. Soc., Perkins Trans. 2
973, 1845.
28. Capasso, S.; Mazzarella, L. Peptides 1998, 19, 389.
2
2
2
Acknowledgements
1
This study supported by grants from Department of
Energy (DE-FG02-87ER60561) and National Institutes
of Health (T-32-CA009015; R01 GM035498). We are
thankful for Mr. Phillip Sherman for performing the
biodistribution studies and preparing animals for micro-
PET imaging. We also thank Mr. James Moskwa for
carrying out and reconstructing the microPET images.
We extend our gratitude to Dr. Robert Koeppe and
Dr. Scott Snyder for their helpful comments.
2
9. Sykes, B. D.; Robertson, E. B.; Dunford, H. B.; Konase-
wich, D. Biochemistry 1966, 5, 697.
3
0. The MMFF94 is one of the most reliable force fields for
protein modeling in terms of predicting conformational
energy differences and barrier height about single-bond
torsions. See Refs. 31–33.
3
1. Levine, I. N. Quantum Chemistry, 5th ed.; Prentice Hall:
Upper Saddler River, NJ, 1999, p 701.
32. Halgren, T. A.; Nachbar, R. B. J. Comput. Chem. 1996,
7, 587.
3. Halgren, T. A. J. Comput. Chem. 1999, 20, 720.
1
3
References and notes
34. Calculations performed with the computational chemistry
software package Spartan 02, release 116; Wavefunction,
Inc.: Irvine, California.
35. Li, J. B. J. Anal. Purif. 1987, 2, 72.
36. Chase, B. H.; Downes, A. M. J. Chem. Soc. 1953,
3874.
37. (a) Levene, P.; Bass, L.; Steiger, R. J. Biol. Chem. 1929, 81,
697; (b) Foye, W.; Kay, D. J. Am. Pharm. Assoc. 1960, 49,
705.
38. Harris, T.; Reilly, T.; DelPrincipe, J. J. Heterocycl. Chem.
1981, 18, 423.
1
2
3
. Fei, Y. J.; Ganapathy, V.; Leibach, F. H. Prog. Nucl. Acid
Res. Mol. Biol. 1998, 58, 239.
. Meredith, D.; Boyd, C. A. Cell. Mol. Life Sci. 2000, 57,
54.
. Rubio-Aliaga, I.; Daniel, H. Trends Pharmacol. Sci. 2002,
3, 434.
7
2
4
5
. Inui, K. I.; Masuda, S.; Saito, H. Kidney Int. 2000, 58, 944.
. Herrera-Ruiz, D.; Knipp, G. T. J. Pharm. Sci. 2003, 92,
6
91.
6
7
. Shen, H.; Smith, D.; Yang, T.; Huang, Y.; Schnermann,
J.; Brosius, F. Am. J. Physiol. Renal. Physiol. 1999, 276,
F658.
. Smith, D. E.; Pavlova, A.; Berger, U. V.; Hediger, M. A.;
Yang, T.; Huang, Y. G.; Schnermann, J. B. Pharm. Res.
39. Samaritoni, J. G.; Demeter, D. A.; Gifford, J. M.; Watson,
G. B.; Kempe, M. S.; Bruce, T. J. J. Agric. Food. Chem.
2003, 51, 3035.
40. Jewett, D. Appl. Radiat. Isot. 1992, 43, 1383.
41. Slightly lower radiochemical yields were obtained when
[ C]methyl triflate was bubbled at ambient temperature.
1
1
1998, 15, 1244.